Clinical Trials · NCT07357415
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- Eli Lilly and Company
- Enrollment
- 600
- Start date
- Jan 2026
- Locations
- 35 sites, 3 countries
- Primary endpoint
- Percent Change from Baseline in Body Weight